Bigul

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

NATCO launches anti blood clot tablet Rivaroxaban in India
17-12-2020
Bigul

NATCO PHARMA LTD. - 524816 - Disclosure Of Related Party Transactions For The Half Year Ended September 30, 2020

Disclosure of Related Party Transactions for the half year ended September 30, 2020
10-12-2020
Bigul

Natco Pharma expects agri business to be key growth lever

Natco is focussing on-field farmer activities, demand generation, farmer demonstrations and awareness and handling statutory needs and requirements
25-11-2020

Hold Natco Pharma; target of Rs 970: ICICI Direct

ICICI Direct recommended hold rating on Natco Pharma with a target price of Rs 970 in its research report dated November 13, 2020.
17-11-2020
Bigul

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation

Investor presentation for the quarter ended September 30, 2020
16-11-2020
Bigul

Natco Pharma receives USFDA nod for cancer treatment drug

Natco Pharma Ltd has on Friday announced that its marketing partner, Breckenridge Pharmaceutical Inc., has received final approval for its Abbreviated
13-11-2020

Earnings Call for Q2FY21 of Natco Pharma

Conference Call with Natco Pharma Management and Analysts on Q2FY21 Performance and Outlook. Listen to the full earnings transcript.
13-11-2020
Bigul

NATCO PHARMA LTD. - 524816 - Board declares Second Interim Dividend

Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 12, 2020, inter alia, has approved the following:- Declaration of second interim dividend of Rs.3 (Rupees three only) per equity share of Rs. 2/- each for the financial year 2020-21.Payment of the said interim dividend will start from December 02, 2020.
12-11-2020
Next Page
Close

Let's Open Free Demat Account